fda peptide warning 2025 september September 16, 2025 - Himswarningletter September 9, 2025 FDA Peptide Warning 2025 September: Navigating Regulatory Scrutiny and Ensuring Patient Safety

Is Hims and Hers FDA-approved The latter half of 2025 is marked by significant regulatory activity from the U.S...September 16, 2025: "Big Pharma says compounded peptides are “unsafe”. Meanwhile, these same companies have FDA warning letters for dirty .... Food and Drug Administration (FDA) concerning peptides, particularly those in the GLP-1 (Glucagon-Like Peptide-1) class2025 FDA TIDES (Peptides and Oligonucleotides) Harvest. A series of warning letters, alerts, and evolving guidance underscore the FDA's increasing focus on the safety, efficacy, and marketing practices surrounding these substances2024年3月5日—The products concerned are the new drugs "Semaglutide", "Tirzepatide" and "Thymalin", which have not been approved by theFDAand have been marketed or .... This intensified scrutiny is directly reflected in various 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest reports and impacts companies ranging from large pharmaceutical manufacturers to compounding facilities.

One of the most prominent developments involves the FDA warning issued to numerous companies, with over 50 GLP-1 and peptide compounding entities receiving warning letters around September 9, 2025.FDA Warning Letter on misbranded and unapproved Drugs These letters, often dated Sept. 9, 2025, highlight objectionable conditions observed during FDA inspections and a review of promotional materials. For instance, Eli Lilly and Company and Novo Nordisk IncBig pharma companies hit with FDA warning letters in drug .... were among those receiving warning letters regarding their GLP-1 receptor agonist medications. Specifically, some of these involved concerns about direct-to-consumer marketing and the omission of crucial safety information, such as the FDA boxed warning for the risk of thyroid C-cell tumors associated with certain GLP-1 RA medications like Zepbound. The FDA has also been proactive in addressing potentially unsafe active pharmaceutical ingredients (APIs). In September 2025, the FDA established a 'Green List Import Alert' (66-80), a mechanism aimed at preventing the import of GLP-1 API's with potential quality concerns. This move, announced on September 05, 2025, is part of a broader effort to protect Americans from illegal and unapproved peptide products. Companies like Chengdu Brilliant Biopharmaceutical Co., Ltd. have been placed on Import Alert 66-40, indicating issues with their drug products available for import.

The regulatory focus extends to the potential for misuse and the introduction of unapproved drugs. For example, PureRawz MARCS-CMS received a warning letter on September 08, 2025, for marketing Tianeptine products as unapproved new drugs. Similarly, the FDA has taken action against telehealth providers suspected of promoting unproven treatmentsThey won't get the real medication in "GLP-1 patches," doctors warn. Sept. 19, 2025, 8:31 AM PDT / Source: TODAY ... There are also no FDA-approved drug .... The broader trend indicates a tightening of oversight across the entire supply chain, from API sourcing to finished product promotion.

Furthermore, the FDA is actively reviewing and sometimes requesting changes to existing warnings.Eli Lilly and Company - 716462 - 09/09/2025 In a significant development in August 2026 (though stemming from earlier reviews), the FDA requested removal of suicidal behavior and ideation warning from certain Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. This indicates a nuanced approach to risk assessment and communication, acknowledging the evolving understanding of drug side effects.

It's crucial for individuals seeking treatments involving peptides, especially GLP-1 medications, to understand the regulatory landscape. The FDA's August 2026 stance on suicidal behavior and ideation warning is a complex issue, and patients should consult with healthcare professionals for accurate information. The FDA also issues warnings about products that are not approved or may pose safety risksEli Lilly and Company - 716485 - 09/09/2025. For example, early in 2025, the FDA issued a warning letter to USA Peptide, highlighting concerns about their productsBig Pharma says compounded peptides are “unsafe .... The agency has also indicated a willingness to streamline processes for certain medical devices, as seen with the FDA "cuts red tape" on Clinical Decision Support, though this contrasts with the strict enforcement seen in the peptide space.

The distinction between FDA-approved therapies and compounded or unapproved alternatives is paramount.引致更改给病人的产品资讯的药物不良反应警示 There are no FDA-approved drug for GLP-1 patches, for instance, leading doctors to warn that "they won't get the real medication in 'GLP-1 patches.2025年9月9日—...warningfor the risk of thyroid C-cell tumors. Obesity and excessive weight and type 2 diabetes mellitus are significant public health ...'" This underscores the importance of verifying the regulatory status of any peptide treatment. The FDA continues to monitor and address issues related to both approved drugs and compounded substances. The agency's actions in September 2025, including the establishment of the 'Green List' and the issuance of numerous warning letters on September 16, 2025 and September 17, 2025, demonstrate a commitment to maintaining public health and ensuring that only safe and effective treatments are available to Americans. For up-to-date information, consumers can refer to FDA warning letters and guidance documents, particularly those issued around September 2025 and into 2026. The FDA's comprehensive approach aims to safeguard against potential risks associated with these powerful peptide therapeuticsFDAhas identified potential significant safety risks when reviewing nominations for bulk drug substances proposed to be included on the 503A or 503B bulks ....